VTS301 parts A and B
69 evidence topics · 18 sources
Objective
Primary objectives of Parts A and B
Objective of the post hoc cerebrospinal fluid biomarker analysis
Location and study date
Registry study dates and enrollment
| Field | Quoted record |
|---|---|
| Study start (actual) | “2015-10” |
| Primary completion (actual) | “2018-03-28” |
| Study completion (actual) | “2018-03-28” |
| Enrollment (actual) | “56” |
| Results first posted | “2023-02-22” |
Study sites by country
Planned number of sites and regulatory oversight
| Field | Quoted record |
|---|---|
| Number of Sites | “Approximately 24 sites worldwide” |
Study design
Multicenter, randomized, double-blind, sham-controlled three-part design
Label description of Trial 1 Parts A and B
Randomization ratios, dose selection, and rescue option
“In Part A, 12 subjects were randomly assigned to one of four study arms (1:1:1:1), and received either one of three dose levels of adrabetadex (900 mg, 1200 mg, or 1800 mg per IT via LP) or sham procedure (no lumbar puncture).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Following dose selection in Part A, 44 additional subjects were randomized 2:1 to receive either study drug at the dose level chosen in Part A (900 mg) or sham.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Subjects enrolled in Part B who manifested significant disease progression according to predefined clinical criteria after treatment of 26 weeks or more had the option to escape the blinded trial early and enter Part C.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dose selection committee and stratification of Part B randomization
Sham procedure and blinding
Sponsor rationale for the sham control
Duration of participation in Parts A and B
Eligibility criteria
Age, age at neurological onset, and diagnosis
Disease severity required at entry
Body weight, prior cyclodextrin, and antipsychotic exclusions
Washout of supplements and investigational treatments
Treatment
Dosage by part in the label
Dose reduction for drug-related adverse events
Intrathecal administration procedure
Sham control intervention in the registry
Study outcomes
Rationale for using the 4-Item NPC severity scale composite score as a co-primary endpoint
Co-primary endpoints: NPC-SS composite score and clinician CGIC at Week 52
Scoring of the 4-item composite and the clinician CGIC
Key secondary endpoints as revised in the statistical analysis plan
Selection of the 4-item composite score for this trial
“Vtesse, Inc., now a Mallinckrodt Pharmaceuticals company, selected the four-item composite score as the primary efficacy endpoint in the Phase 2/3 multicenter clinical trial of intrathecal adrabetadex in NPC1” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The NPC-SS and particularly the 4- and 5-item scales represent key domains identified by families and clinicians as important to quality of life.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All domains were rated except those involving hearing as hearing information was being monitored seperately in the trial to track this as an adverse event, the hearing rating was not part of the efficacy score as the drug can cause hearing loss, and hearing information might have unblinded the NPC-SS raters to treatment status.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Inter-rater reliability of central NPC-SS scoring in this trial
“The objective of the study was to examine the inter-rater reliability of the NPC-SS in a Phase 2/3 clinical trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Clinical data recorded at each study site were distributed to two independent blinded central raters to generate a severity score.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The average ICCs for absolute agreement for the 4-item and 5-item scales, respectively, were ICC (3,2) = 0.95 [95% CI = 0.93, 0.97] and 0.96 [95% CI = 0.93, 0.97] for the multiple assessment, and ICC (3,1) = 0.91 [95% CI = 0.87, 0.94] and 0.92 [95% CI = 0.87, 0.94] for the single assessment (Supplemental Data, Table 9).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For the NPC-SS 4-item composite score, the average kappa was 0.36 [95% CI= 0.31, 0.42], the average weighted kappa was 0.76 [95% CI= 0.73, 0.79], and the average percent agreement between raters was 40.9% (95% CI= 35.2, 46.6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These results support the NPC-SS, including derived 4- and 5-item composite scores, as reliable measures for use in a clinical trial setting.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Development of the NPC clinical severity scale
“Thus, we developed a clinical severity scale to characterize and quantify disease progression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Both patient cohorts showed a linear increase in severity scores over time.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Content validity and meaningful change of the 5-domain scale
“Domains identified as most important by clinicians, caregivers, and patients (independent of current age, age of onset, and disease severity) were Ambulation, Swallow, Cognition, Speech, and Fine Motor Skills, indicating content validity of the 5-domain NPCCSS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Meaningful change using trial data and interviews with NPC experts (n = 5) and patients/caregivers (n = 28) suggested that a 1-category change on a domain is equivalent to 1-point change or greater in the 5-domain NPCCSS total score.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
International Delphi consensus on severity scales
“Consensus was reached (74%) for the 17-domain NPCCSS scale as the first choice in clinical trial settings, but the domains measured in the 5-domain scale should be prioritised as the primary endpoints.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Several scales have been developed and published over the past two decades but, essentially, all are based on a four-domain scale initially developed by Iturriaga et al.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Convergent validity of scale domains, including data from this trial
“Participants were drawn from several studies performed at two sites at which participants with clinically and biochemically confirmed NPC were followed with regular clinical evaluations, including a natural history study for NPC (NCT00344331), a phase 1/2a trial of intrathecal 2-hydroxypropyl-beta-cyclodextrin (adrabetadex, NCT01747135), a phase 2b/3 trial of adrabetadex (NCT02534844), and an expanded access program for treatment of NPC with adrabetadex (IND119856).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The 5DNPCCSS domains were significantly related in the expected directions to their respective direct assessments, supporting their construct validity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the years since its publication, researchers and regulators have noted that the wide-ranging composition of the NPC-CSS-17, meant to capture the full range of clinical presentation, might reduce its ability to detect an effect of intervention.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Planned sample size and its basis
Power calculation assumptions
Description of analysis sets
Analysis populations in the protocol
Modified intent-to-treat population as defined in the statistical analysis plan
Analysis populations in the registry results
Primary analysis method and handling of missing data
Clinician CGIC analysis and hierarchical testing of key secondary endpoints
Statistical methods of the post hoc biomarker analysis
Results
Participant disposition
Participant flow in the ClinicalTrials.gov record
Baseline characteristics
Baseline demographics of the intent-to-treat population in the ClinicalTrials.gov record
Baseline weight, miglustat use, seizures, symptom duration, and total severity score
| Characteristic | Adrabetadex (N=38) | Sham control (N=18) |
|---|---|---|
| Weight (kg), mean (SD) | “48.1 (25.27)” | “40.2 (18.98)” |
| Miglustat use, n (%) | “25 (66)” | “9 (50)” |
| Seizures, n (%) | “15 (39)” | “5 (28)” |
| Duration of neurologic symptoms (years), mean (SD) | “7.1 (4.15)” | “5.9 (5.16)” |
| Baseline NPC-CSS total score (minus hearing/ABR), mean (SD) | “17.8 (6.48)” | “16.9 (8.16)” |
Label demographics of participants receiving up to 900 mg and sham
Cerebrospinal fluid biomarker analysis subset
Efficacy results
Sponsor statements of the Parts A and B result
Secondary endpoints reported in the ClinicalTrials.gov results
| Outcome measure | Sham control | Adrabetadex |
|---|---|---|
| NPC-SS total score excluding hearing and ABR, change at Week 52, mean (SD) | “-0.74(2.357)” | “-0.34(4.226)” |
| Responders on NPC-SS total score excluding hearing and ABR at Week 52, participants | “13” | “22” |
| Participants who qualified for the rescue option | “2” | “2” |
| Time to one-point worsening in NPC-SS composite score, median days (95% CI) | “118 (55 to 364)” | “169 (70 to 278)” |
| 9-Hole Peg Test, change at Week 52, seconds, mean (SD) | “-1.49(15.958)” | “-1.79(34.760)” |
| Annualized rate of change (slope) of NPC-SS composite, mean (SD) | “-0.05(1.640)” | “0.08(2.441)” |
Timed Up and Go test and total NPC-SS including hearing
| Outcome measure | Sham control | Adrabetadex |
|---|---|---|
| Timed Up and Go, change at Week 52, seconds, mean | “0.86” | “2.70” |
| Timed Up and Go, change at Week 52, seconds, SD | “19.232” | “9.633” |
| Total NPC-SS with hearing and ABR, change at Week 52, mean | “0.000” | “0.75” |
| Total NPC-SS with hearing and ABR, change at Week 52, SD | “1.000” | “4.500” |
Change in each NPC-SS domain at Week 52
| Domain, change from baseline at Week 52 | Sham control, mean | Sham control, SD | Adrabetadex, mean | Adrabetadex, SD |
|---|---|---|---|---|
| Ambulation | “0.00” | “0.679” | “0.06” | “1.434” |
| Fine motor | “0.07” | “0.917” | “0.24” | “1.103” |
| Cognition | “-0.14” | “0.663” | “0.06” | “0.919” |
| Swallowing | “0.00” | “1.109” | “-0.29” | “1.360” |
| Memory | “0.00” | “0.784” | “0.18” | “1.218” |
| Speech | “0.14” | “0.663” | “-0.18” | “0.673” |
| Eye movement | “0.00” | “0.679” | “-0.06” | “0.547” |
| Hearing | “-0.22” | “1.302” | “1.14” | “1.236” |
| Seizures | “-0.50” | “1.286” | “-0.06” | “0.952” |
Post hoc cerebrospinal fluid biomarkers at Week 52 in adrabetadex-treated participants
Health-related quality of life and patient-reported outcomes
Caregiver-rated CGIC responders at Week 52
Safety results
Deaths, serious adverse events, and other adverse events by arm
| Event | Part A adrabetadex 900 mg | Part A adrabetadex 1200 mg | Part A adrabetadex 1800 mg | Part A sham | Part B adrabetadex 900 mg | Part B sham |
|---|---|---|---|---|---|---|
| All-cause mortality | “0/3 (0.00%)” | “0/3 (0.00%)” | “1/3 (33.33%)” | “0/3 (0.00%)” | “0/29 (0.00%)” | “1/15 (6.67%)” |
| Any serious adverse event | “1/3 (33.33%)” | “0/3 (0.00%)” | “2/3 (66.67%)” | “0/3 (0.00%)” | “16/29 (55.17%)” | “3/15 (20.00%)” |
| Any other (non-serious) adverse event | “3/3 (100.00%)” | “3/3 (100.00%)” | “3/3 (100.00%)” | “3/3 (100.00%)” | “28/29 (96.55%)” | “14/15 (93.33%)” |
Serious adverse events of hearing, seizure, and aspiration in Part B
| Serious adverse event | Part B adrabetadex 900 mg | Part B sham |
|---|---|---|
| Deafness | “3/29 (10.34%)” | “0/15 (0.00%)” |
| Hearing impaired | “3/29 (10.34%)” | “1/15 (6.67%)” |
| Seizure | “3/29 (10.34%)” | “1/15 (6.67%)” |
| Aspiration | “2/29 (6.90%)” | “1/15 (6.67%)” |
| Pneumonia aspiration | “3/29 (10.34%)” | “0/15 (0.00%)” |
Common non-serious adverse events in Part B
| Adverse event | Part B adrabetadex 900 mg | Part B sham |
|---|---|---|
| Vomiting | “15/29 (51.72%)” | “2/15 (13.33%)” |
| Back pain | “14/29 (48.28%)” | “0/15 (0.00%)” |
| Fatigue | “12/29 (41.38%)” | “2/15 (13.33%)” |
| Pyrexia | “12/29 (41.38%)” | “3/15 (20.00%)” |
| Gait disturbance | “11/29 (37.93%)” | “2/15 (13.33%)” |
| Hypoacusis | “10/29 (34.48%)” | “0/15 (0.00%)” |
| Fall | “10/29 (34.48%)” | “1/15 (6.67%)” |
| Diarrhoea | “9/29 (31.03%)” | “1/15 (6.67%)” |
| Headache | “9/29 (31.03%)” | “1/15 (6.67%)” |
| Hearing impaired | “8/29 (27.59%)” | “6/15 (40.00%)” |
| Nausea | “8/29 (27.59%)” | “0/15 (0.00%)” |
| Ataxia | “7/29 (24.14%)” | “2/15 (13.33%)” |
| Tinnitus | “5/29 (17.24%)” | “0/15 (0.00%)” |
Company summary of safety in the Parts A and B safety population
Study limitations
Summary: design limitations of Parts A and B
- Control and observed progression: Parts A and B compared intrathecal VTS-270 with a sham procedure of 1 to 2 small needle pricks on the lower back with no lumbar puncture. At Week 52 the mean change from baseline in the NPC-SS composite score was -0.1 (SD 1.55) in the sham group (n = 18) and 0.0 (SD 2.45) in the adrabetadex group (n = 38). The company stated that “Neither the VTS-270 nor the placebo arm showed disease progression”, and a data request summary states that the trial failed to show benefit “as the sham group had little progression” and that sham-controlled trials in NPC “are highly challenging due to variability of the disease”.
- Blinding: the participant, outcomes assessor, care provider, and investigator were blinded. The hearing rating was excluded from the efficacy score because the drug can cause hearing loss and “hearing information might have unblinded the NPC-SS raters to treatment status”. NPC-SS scores were generated by two central raters, which the inter-rater reliability study lists as a limitation.
- Sample size: the sample size was based on the potential number of available subjects for this ultra-rare disorder. The plan of approximately 51 subjects gave the ANCOVA 79% power under assumed 52-week increases of 0 to 0.2 points with VTS-270 and 1.6 to 1.9 points with sham. The statistical analysis plan states that 54 subjects were randomized; the prescribing information states that Parts A and B enrolled 56 treatment-naïve participants.
- Randomization ratio: one publication states that Part A randomized 12 subjects 1:1:1:1 to three dose levels or sham, and protocol amendment 15 states a 3:1 ratio in Part A. Both state a 2:1 ratio in Part B.
- Analysis sets: the registry analyzed 38 adrabetadex and 18 sham participants for the co-primary NPC-SS composite endpoint and 34 and 14 for the annualized slope. The prescribing information describes 32 participants who received up to 900 mg and 18 in the sham-control group. The statistical analysis plan restricts the modified intent-to-treat population to subjects who received at least one dose of 900 mg of VTS-270 or sham control, and the registry defines it as all randomized participants who received at least one treatment (sham or adrabetadex). The statistical analysis plan also changed the protocol's list of key secondary endpoints.
- Early exit: Part B participants with significant disease progression after 26 weeks or more could leave the blinded trial early and enter Part C; 2 sham and 2 adrabetadex participants qualified for this rescue option.
- Concomitant miglustat: randomization in Part B was stratified by miglustat use and baseline NPC-SS level, but the statistical analyses were not stratified. At baseline, 25 (66%) adrabetadex and 9 (50%) sham participants used miglustat. A post hoc analysis reported that subjects receiving miglustat, with or without adrabetadex, showed evidence of disease stabilization, while subjects receiving adrabetadex without miglustat showed disease worsening comparable to sham subjects not on miglustat.
- Biomarkers: cerebrospinal fluid was collected only from subjects receiving study drug; sham-control subjects provided urine and plasma. The post hoc biomarker study of 34 participants tested within-group changes with the Wilcoxon signed-rank test, with nominal significance at P<0.05 without adjustment for multiplicity.
- Sponsor statements: the company stated that it was evaluating this portion of the study “in order to ensure the data was properly captured and of the highest quality”. A community update stated that a manuscript summarizing the data and experience from the VTS-301 trial was being prepared.